Interleukin-8 is not a predictive biomarker for the development of the acute promyelocytic leukemia differentiation synd
- PDF / 740,993 Bytes
- 7 Pages / 595.276 x 790.866 pts Page_size
- 57 Downloads / 181 Views
(2020) 20:821
RESEARCH ARTICLE
Open Access
Interleukin-8 is not a predictive biomarker for the development of the acute promyelocytic leukemia differentiation syndrome Luciana Yamamoto de Almeida1,2, Diego Antonio Pereira-Martins1,2, Ana Sílvia Gouvêa Lima1, Márcia Sueli Baggio3, Luisa Corrêa de Araujo Koury1, Ana Paula Lange1,2, Sarah Cristina Bassi2, Priscila Santos Scheucher1 and Eduardo Magalhães Rego1,2,4*
Abstract Background: Differentiation syndrome (DS) is the main life-threatening adverse event that occurs in acute promyelocytic leukemia (APL) patients treated with all-trans retinoic acid (ATRA). Cytokine imbalances have been reported to play role during the developing of acute promyelocytic leukemia differentiation syndrome (APL-DS). However, the relationship between the plasma cytokine levels and their prognostic value for the prediction of DS developing in patients with APL during the treatment with ATRA and anthracyclines has not been previously reported. Methods: In this study, we followed an APL cohort (n = 17) over 7 days of ATRA therapy in DS (n = 6) and non-DS groups (n = 11). Interleukin (IL)-1β, IL-6, IL-8, IL-10, IL-12p70 and TNF-α were measured in the peripheral blood plasma from 17 patients with APL and 11 healthy adult controls by using the cytometric bead array method. Results: In non-DS patients, IL-8 plasma levels were significantly reduced in the seventh day of ATRA treatment (34.16; 6.99 to 147.11 pg mL− 1 in D0 vs. 10.9; 0 to 26.81 pg mL− 1 in D7; p = 0.02) whereas their levels did not discriminate between DS and non-DS development during the entire induction period (all p > 0.05 in D0, D3, and D7). No significant differences were found in IL-6 levels between groups (p > 0.05 in D0-D7). Other cytokines tested were all undetectable in patients with APL or healthy controls. Conclusions: We demonstrated that the modulation of IL-8 following ATRA treatment may occur regardless of the development of DS and, therefore, does not appear to be a predictive biomarker to monitor the APL-DS. Keywords: Acute promyelocytic leukemia, Differentiation syndrome, Interleukin-6 (IL-6), Interleukin-8 (IL-8)
* Correspondence: [email protected] 1 Hematology Division, Department of Medical Images, Hematology, and Clinical Oncology, University of Sao Paulo at Ribeirao Preto Medical School, Ribeirao Preto, Brazil 2 Center for Cell Based Therapy, University of Sao Paulo at Ribeirao Preto Medical School, Ribeirao Preto, Brazil Full list of author information is available at the end of the article © The Author(s). 2020 Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated othe
Data Loading...
